Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis
Authors' conclusion
Monthly cost offsets for persistent tirzepatide users versus untreated individuals grew over time, offsetting $319 (ranging from $94 to $544) tirzepatide costs by 12-18 months.
Study context
- Population
- Adults >55 years with obesity, or overweight with ≥1 weight-related comorbidity, without T2D; US Komodo Research Dataset, 8 November 2022 to 30 September 2025matched cohort
- Participants
- 15,843 vs 15,843
- Exposure
- Tirzepatide vs no treatment
- Tirzepatiden = 15,843
- Controln = 15,843reference
- Outcome
- Change in all-cause healthcare costs (excluding tirzepatide; per-person-per-month), DiD between cohorts
- Follow-up
- 3-6, 6-12 and 12-18 months
Methodological detailspropensity score-matched, difference in differences (DiD) framework, inverse-probability-of-censoring-weights
- Propensity score-matched
- Difference in differences (DiD) framework
- Inverse-probability-of-censoring-weights
Main finding
As reported in the abstract
All-cause healthcare costs per-person-per-month, DiD · 6-12 and 12-18 months
DiD
-$145
95% CI −266 to −25P = 0.022
6-12 months; 12.3% reduction
DiD
-$319
95% CI −544 to −94P = 0.015
12-18 months; 25.4% reduction
Observational data: associations, not effects.
Further findings
| Outcome | IRR (95% CI) | P value | |
|---|---|---|---|
| Inpatient/ED visits · 12-18 months | 0.69 (0.50–0.94) | P = 0.021 | |
| 0.512Incidence rate ratio (log scale) |
| Outcome | Estimate | P value |
|---|---|---|
| All-cause healthcare costs DiD, pairwise censoring · 6-12 and 12-18 monthsTirzepatide vs Control · 6-12 months · pairwise censoring | DiD -$181 (CI −319 to −43) | P = 0.021 |
| All-cause healthcare costs DiD, pairwise censoring · 6-12 and 12-18 monthsTirzepatide vs Control · pairwise censoring | DiD -$607 (CI −1007 to −207) | P = 0.023 |
| Medical costs · 12-18 monthsHigher medical costs in controls | -$211 (CI -$407, -$15) | P = 0.065 |
Original publication
Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis. Diabetes Obes Metab. Published 24 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →